Turning Point in the Treatment of Mantle Cell Lymphoma

• Motokura Toru

  Division of Clinical Laboratory Medicine, Department of Pathophysiological and Therapeutic Science, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan

抄録

Mantle cell lymphoma (MCL) is an incurable type of B-cell lymphoma. It is typically composed of small-to-medium-sized cleaved lymphoid cells with cyclin D1 protein expression due to the chromosomal translocation t(11;14)(q13;q32). Even with the development of rituximab, an anti-CD20 antibody drug, the long-term outcome of patients with MCL has not improved. Recently, new agents have been used in clinical settings, and the outcome of patients with MCL is expected to improve. The treatment of MCL may be at a turning point from intensive chemotherapy to chemotherapy-free treatment. In this study, a recent progress in the diagnosis and treatment of MCL is reviewed.

収録刊行物

• Yonago Acta Medica

  Yonago Acta Medica 62 (1), 001-007, 2019

  ヨナゴ・アクタ・メディカ刊行会

キーワード

• General Medicine

詳細情報

• CRID: 1390564238093468928
• NII論文ID: 130007626222
• NII書誌ID: AA00892882
• DOI: 10.33160/yam.2019.03.001
• ISSN: 13468049
• ISSN: 05135710
• Web Site: https://repository.lib.tottori-u.ac.jp/records/4762
• Web Site: https://www.jstage.jst.go.jp/article/yam/62/1/62_2019.03.001/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2020166123
• 本文言語コード: en
• データソース種別:
  • JaLC
  • IRDB
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可